Recommanded Product: 61-82-5. Halawa, AH; Eskandrani, AA; Elgammal, WE; Hassan, SM; Hassan, AH; Ebrahim, HY; Mehany, ABM; El-Agrody, AM; Okasha, RM in [Halawa, Ahmed H.; Elgammal, Walid E.; Hassan, Saber M.; Hassan, Ahmed H.; El-Agrody, Ahmed M.] Al Azhar Univ, Fac Sci, Chem Dept, Cairo 11284, Egypt; [Eskandrani, Areej A.; Okasha, Rawda M.] Taibah Univ, Fac Sci, Chem Dept, Medina 30002, Saudi Arabia; [Hassan, Ahmed H.] Jazan Univ, Fac Sci, Chem Dept, Jazan 45142, Saudi Arabia; [Ebrahim, Hassan Y.] Helwan Univ, Fac Pharm, Pharmacognosy Dept, Cairo 11795, Egypt; [Mehany, Ahmed B. M.] Al Azhar Univ, Fac Sci, Zool Dept, Cairo 11284, Egypt published Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors in 2019.0, Cited 65.0. The Name is 1H-1,2,4-Triazol-5-amine. Through research, I have a further understanding and discovery of 61-82-5.
Protein kinases orchestrate diverse cellular functions; however, their dysregulation is linked to metabolic dysfunctions, associated with many diseases, including cancer. Mitogen-Activated Protein (MAP) kinase is a notoriously oncogenic signaling pathway in human malignancies, where the extracellular signal-regulated kinases (ERK1/2) are focal serine/threonine kinases in the MAP kinase module with numerous cytosolic and nuclear mitogenic effector proteins. Subsequently, hampering the ERK kinase activity by small molecule inhibitors is a robust strategy to control the malignancies with aberrant MAP kinase signaling cascades. Consequently, new heterocyclic compounds, containing a sulfonamide moiety, were rationally designed, aided by the molecular docking of the starting reactant 1-(4-((4-methylpiperidin-1-yl)sulfonyl)phenyl)ethan-1-one (3) at the ATP binding pocket of the ERK kinase domain, which was relying on the molecular extension tactic. The identities of the synthesized compounds (4-33) were proven by their spectral data and elemental analysis. The target compounds exhibited pronounced anti-proliferative activities against the MCF-7, HepG-2, and HCT-116 cancerous cell lines with potencies reaching a 2.96 mu M for the most active compound (22). Moreover, compounds 5, 9, 10b, 22, and 28 displayed a significant G2/M phase arrest and induction of the apoptosis, which was confirmed by the cell cycle analysis and the flow cytometry. Thus, the molecular extension of a small fragment bounded at the ERK kinase domain is a valid tactic for the rational synthesis of the ERK inhibitors to control various human malignancies.
Recommanded Product: 61-82-5. Bye, fridends, I hope you can learn more about C2H4N4, If you have any questions, you can browse other blog as well. See you lster.
Reference:
Article; Safari, Niloufar; Shirini, Farhad; Tajik, Hassan; Journal of Molecular Structure; vol. 1201; (2020);,
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics